Antineutrophil Cytoplasmic Antibody-associated Vasculitis Management 2020: Where Are We Now?
The Journal of Rheumatology
MetadataShow full item record
Jayne, D. (2021). Antineutrophil Cytoplasmic Antibody-associated Vasculitis Management 2020: Where Are We Now?. J Rheumatol, 48 (4), 479-481. https://doi.org/10.3899/jrheum.201351
The management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) has come a long way from the first postmortem descriptions of the diseases in the 1930s and 1950s1 Pivotal phases have been the introduction of glucocorticoids (GC) and cyclophosphamide (CYC), the association with ANCA in the 1980s, and consensus classification and nomenclature systems from 1990 onwards2.
Humans, Antibodies, Antineutrophil Cytoplasmic, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
External DOI: https://doi.org/10.3899/jrheum.201351
This record's URL: https://www.repository.cam.ac.uk/handle/1810/330740
All rights reserved
Licence URL: http://www.rioxx.net/licenses/all-rights-reserved